Angiopoietin-like protein 8: An attractive biomarker for the evaluation of subjects with insulin resistance and related disorders. (November 2017)

• Record Type: Journal Article
• Authors: Wang, Su; Hong, Xiafei; Tu, Zhigang; Yuan, Guoyue
• Is Part Of: Diabetes research and clinical practice. Volume 133(2017)
• Page Start: 168
• Page End: 177
• Publication Date: 2017-11
• Subjects: ANGPTL8 -- Insulin resistance -- Obesity -- Type 2 diabetes -- Nonalcoholic fatty liver disease -- Polycystic ovary syndrome; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2017.08.025
• Languages: English
• ISSNs: 0168-8227

Abstract

Highlights: We exploit whether ANGPTL8 could be applied for clinical biomarker to predict insulin resistance and related disorders. Discuss the controversial results involving the relationship between ANGPTL8 and T2DM, obesity, NAFLD, PCOS. Some alternative explanations were taken into account for the controversial published results. Abstract: Insulin resistance is prevalent worldwide and is associated with many metabolic diseases, in particular, type 2 diabetes mellitus (T2DM), obesity, nonalcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS) and metabolic syndrome (MetS). Angiopoietin-like protein 8 (ANGPTL8), a newly-identified secreted protein composing of 198 amino acids, is enriched in the liver of human. Considering its promising potential for β-cell proliferation and therapeutic prospect for diabetes, ANGPTL8 has aroused extensive interests. However, a recent collaborative study confirmed that ANGPTL8 didn't stimulate dramatic β-cell regeneration. At present, a controversial scientific discussion on whether and how ANGPTL8 regulate insulin resistance has been ongoing. Interestingly, several in vitro and in vivo studies have suggested the complex roles of ANGPTL8 in insulin resistance. Data resulting from cross-sectional and longitudinal researches in human individuals involving the influence of ANGPTL8 on the development of insulin resistance were controversial. We therefore summarize currently clinical literature to exploit whether this exciting hormone could be applied for clinical application as a potential clinical biomarker to predict insulin resistance and related disorders.